

Do You Have Hormone-Positive, HER2-Negative Breast Cancer That Has Spread?

Clinical trial S1703 is a research study for people with breast cancer that has spread to other places in the body. It is for people with cancer that is hormone-positive (ER positive, PR positive, or both) and HER2-negative.



What is the purpose of the S1703 study? Research

Researchers will compare different approaches for monitoring breast cancer during treatment.

They want to find out if a new approach:

- Works just as well as the usual approach
- Improves quality of life for patients
- Helps patients have less anxiety ("scanxiety") about imaging scans (such as PET, CT, or MRI scans)
- Lowers healthcare costs



Who can join the study?

This study is for people, age 18 or older, who have started treatment or plan to start treatment for breast cancer. Ask your doctor about all study requirements.

To join the study, you must have breast cancer that is:

- Metastatic – This means it has spread to other places in your body outside of the breast.
- Estrogen receptor positive (ER+), progesterone receptor positive (PR+), or both – This means the cancer has certain proteins that attach to estrogen or progesterone hormones.
- HER2-negative - This means the cancer has normal HER2 protein levels.



What can I expect during the study?

You will receive cancer treatment as usual. To determine which approach your doctor will use to monitor the cancer, you will be randomly assigned to 1 of 2 study groups:

Group 1 (Usual Approach):

- At least every 12 weeks, you will have imaging scans to monitor the cancer. Your doctor will determine if you also need to have a blood test called a serum tumor marker (STM) test.

Group 2 (New Approach):

- Every 4 to 8 weeks, you will have an STM blood test. The results will determine when you have imaging scans to monitor the cancer.

If your doctor has any concerns for any reason, they can still order imaging scans for you at any time during your care.

By joining this study, you:

- May get free access to a new approach for monitoring cancer
- Receive support and close monitoring from your study care team
- Help advance breast cancer research. This study may change and improve how patients get cancer care in the future.



For more information, contact:

Version June 27, 2022